CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PsychoeducationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D019337 Hematologic Neoplasms NIH 0.38

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001909 Leukemia HPO 0.30

There is one clinical trial.

Clinical Trials

1 A Pilot Study Evaluating Feasibility, Acceptability, Usability, Satisfaction and Preliminary Efficacy of an Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy

The purpose of this study is to determine which of two approaches is helpful to support caregivers of patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptors (CAR) T-cell therapy at Seidman Cancer Center. This study will take start before you begin treatment until 2 months after your hospital discharge.

NCT04390542 Blood Cancer Behavioral: Psychoeducation
MeSH:Hematologic Neoplasms
HPO:Hematological neoplasm Leukemia

Primary Outcomes

Description: Feasibility, as measured by time to identify and recruit dyads (benchmark 3 months)

Measure: Time to identify and recruit dyads in months

Time: 2 months post-hospital discharge, an average of 2 months

Description: Feasibility, as measured by accrual rates of eligible participants

Measure: Accrual rates

Time: 2 months post-hospital discharge, an average of 2 months

Description: Feasibility, as measured by retention rate

Measure: Retention rate

Time: 2 months post-hospital discharge, an average of 2 months

Description: Feasibility as measured by completion of data collection across study timepoints

Measure: Data collection completion rate

Time: 2 months post-hospital discharge, an average of 2 months

Description: Acceptability, as measured by average acceptability scale scores, with overall score ranging from 6-30. According to prior research, a score of 80% of higher (total score of 24 or higher) is considered acceptable for use.

Measure: Average acceptability scale scores

Time: 2 months post-hospital discharge, an average of 2 months

Description: Usability, as measured by average System Usability Scale scores. This is a 10 item scale scored on a 5 point Likert scale with total summed scores ranging from 0-50. Total scores are multiplied by 2 to produce an overall score ranging from 0-100 with scores > 68 considered to be above average usability.

Measure: Average System Usability Scale scores

Time: 2 months post-hospital discharge, an average of 2 months

Description: Caregiver satisfaction will be evaluated by having caregivers evaluate their satisfaction with each of the 6 modules at the end of each module. After completing each module, they will be sent via REDCap a single item evaluation scale (0 -10; 0=Not at all satisfied; 10=Highly satisfied). Scores >7 will be considered acceptable. Mean and standard deviation to describe subjects' overall satisfaction with the intervention reported.

Measure: Mean caregiver satisfaction

Time: 2 months post-hospital discharge, an average of 2 months

Description: End-of-study caregiver satisfaction, as measured by end of study exit interview that assesses overall satisfaction with intervention (Likert Scale). Scores range from 0 to 10, with higher scores indicating more satisfaction.

Measure: End-of-study caregiver satisfaction scores

Time: 2 months post-hospital discharge, an average of 2 months

Secondary Outcomes

Description: Caregiver anxiety as measured by PROMISR Short Form v1.0 - Anxiety scores. Scores range from 1 to 5, with higher scores indicating worse anxiety. Evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)—between and within model- controlling for caregiver age, race, and gender

Measure: Caregiver anxiety as measured by PROMISR Short Form v1.0 - Anxiety scores

Time: Baseline, hospital discharge, 2 months post hospital discharge

Description: Caregiver HRQOL, evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)—between and within model- controlling for caregiver age, race, and gender. HRQOL scores range from 1 to 5, with higher scores indicating better outcomes.

Measure: Caregiver Healthcare Related Quality Of Life (HRQOL)

Time: Baseline, hospital discharge, 2 months post hospital discharge

Description: Distress as measured by the NCCN distress thermometer. Thermometer scores range from 0 to 10, with higher scores indicating worse distress. Prior to administration of the distress thermometer measure, each caregiver will be asked if they are experiencing distress related to Covid-19 (yes/no). The distress thermometer asking them to rate their distress in the past week including today. The Covid-19 variable will be included as a covariate in the analyses. Evaluated for changes over 3 time points using repeated measures analysis of variance (RMANOVA)—between and within model- controlling for caregiver age, race, and gender

Measure: Distress as measured by the the NCCN distress thermometer

Time: Baseline, hospital discharge, 2 months post hospital discharge

Related HPO nodes (Using clinical trials)

HP:0004377: Hematological neoplasm
Genes 351
CHEK2 FANCE CBL TERT ATRX TERT RPS24 BIRC3 GATA1 STS JAK2 FANCL POT1 NOP10 TERT GATA2 RFWD3 MLH1 TCF4 LIG4 NPM1 RARA CD19 SH3GL1 CASP10 PDGFRA RPL5 BRIP1 ERBB3 RUNX1 KRAS PIGL CD81 SAMD9 THPO DYNC2LI1 RPS26 RAG2 WRAP53 CBL GFI1B STAT3 ABL1 LPP ATM TP53 IGH NRAS RPL26 RPS29 CALR ASXL1 CEBPA MALT1 ELANE CD19 TET2 NUP214 MSH2 CCND1 HAX1 SMARCD2 MYD88 EVC RAD54B RUNX1 FANCF SAMHD1 TRIP13 TNFRSF13B RUNX1 TP53 RPS10 CALR FLT3 BCL10 NRAS SETBP1 MSH2 TNFRSF13C SH2B3 FANCC BCL6 BLM CD28 LIG4 MCM4 FANCG GATA2 MYD88 GBA BCL2 GINS1 TET2 IL7R MYSM1 SLX4 KIT NBN RASGRP1 RB1 TINF2 RECQL4 FASLG PRF1 BRD4 TREX1 THPO SMPD1 FANCI NBEAL2 BUB3 ATM PDGFRB FAS FANCD2 RPS28 ZAP70 FANCA BAX LIG4 RPL11 LYST ADA CHIC2 POLE XIAP KRAS RTEL1 EVC2 XRCC2 SCN10A MPL CTLA4 ASXL1 MDM2 SAMD9L GATA2 RNASEH2B CBL JAK2 PNP UBE2T CBFB ARHGAP26 SCN11A MPL TINF2 F13A1 DCLRE1C SRP72 BCR SBDS ADA ICOS NAGS FANCB GNB1 TAL1 PIGA NUP214 TYROBP GFI1 RAD51 BCL10 TREM2 ICOS CEP57 MLH1 IGH PICALM FANCM ERCC4 FANCD2 RPS15A FANCE PIK3R1 ELANE WIPF1 IL2RG GATA1 SRP54 RAF1 LIG4 NFKB1 PTPN11 XRCC4 SRP54 TET2 TET2 PTEN EP300 CASP10 DNASE1L3 PTPN11 MS4A1 GATA2 RASGRP1 NUTM1 NTHL1 ETV6 TET2 NPM1 PIGL GFI1 RPS14 BCL10 WAS RPL18 SH2B3 RMRP SRSF2 DNMT3A DNAJC21 RPS27 RPS7 MPL FOXP1 DNMT3A CALR ASXL1 MPL TNFRSF13C TSR2 RUNX1 DKC1 APC ADAR RAD51C BRCA2 GLI1 IFIH1 SCN9A CDKN2A SH2D1A KLHDC8B NSUN2 CREBBP PGM3 SRP54 SBDS SH2B3 DNAJC21 CHD7 MPL BCR GATA2 BRCA1 BUB1B TERC CALR TNFRSF13B CD28 SAMD9L AAGAB BCR TP53 TCIRG1 ADA2 HSPA9 PIK3CA SRSF2 RNF43 TERT CR2 COL14A1 IGH RMRP FANCG IL2RG JAK2 KIF11 FLT3 JAK2 MAD2L2 FANCC RPS17 PARN NUMA1 RAD54L MSH6 RPL35 BRAF RNASEH2C CD70 SF3B1 MSH6 DDX41 TERC RECQL4 PMS2 RPL35A CCND1 BUB1 SF3B1 TERC TET2 RFWD3 CTLA4 MYC DNAJC21 TNFSF12 MAGT1 BLM FANCA KIT ITK RPL31 MLLT10 RPL15 RNASEH2A CR2 NHP2 TAL2 RPS14 NBN CD27 TCF4 NFKB2 RPS19 TNFSF12 HLA-DRB1 FAS RHOH NF1 ABL1 USB1 BUB1B NBN TET2 LIG4 PRKCD CTC1 JAK2 RPL27 PRKCD RPS19 TNFRSF1B BRCA2 DKC1 PALB2 F13B ATRX RAG1 TP63 EFL1 TNFRSF1B TET2 TET2 JAK2 KRAS
Protein Mutations 0
SNP 0
HP:0001909: Leukemia
Genes 190
TREM2 CBL TERT CEP57 PICALM ATRX TERT FANCD2 RPS15A RPS24 FANCE PIK3R1 GATA1 STS ELANE WIPF1 JAK2 GATA1 SRP54 LIG4 POT1 GATA2 PTPN11 MLH1 XRCC4 SRP54 TET2 TET2 LIG4 EP300 NPM1 RARA SH3GL1 PDGFRA RPL5 ERBB3 RUNX1 KRAS PIGL GATA2 NUTM1 ETV6 PIGL THPO DYNC2LI1 RPS26 GFI1 CBL WAS RPL18 SH2B3 ABL1 LPP ATM SRSF2 TP53 NRAS DNMT3A DNAJC21 RPS27 RPS7 MPL RPL26 DNMT3A RPS29 CALR ASXL1 CEBPA ELANE TSR2 RUNX1 DKC1 APC ADAR NUP214 GLI1 HAX1 IFIH1 SCN9A MYD88 EVC RUNX1 SAMHD1 NSUN2 CREBBP TRIP13 SRP54 SBDS SH2B3 RUNX1 DNAJC21 TP53 RPS10 MPL BCR GATA2 CALR BUB1B FLT3 CALR NRAS SETBP1 MSH2 SH2B3 SAMD9L FANCC BCR TCIRG1 BLM ADA2 PIK3CA SRSF2 FANCG GATA2 MYD88 KIF11 TET2 FLT3 JAK2 KIT RPS17 NBN RB1 NUMA1 BRD4 TREX1 THPO SMPD1 RPL35 BUB3 RNASEH2C PDGFRB SF3B1 RPS28 MSH6 DDX41 PMS2 RPL35A BAX BUB1 TERC TET2 DNAJC21 RPL11 CHIC2 BLM FANCA KIT RPL31 MLLT10 RPL15 RNASEH2A KRAS TAL2 EVC2 RPS14 SCN10A RPS19 MPL ASXL1 SAMD9L RNASEH2B CBL JAK2 NF1 ABL1 CBFB ARHGAP26 BUB1B NBN SCN11A TET2 MPL JAK2 F13A1 RPL27 BCR BRCA2 SBDS F13B GNB1 TAL1 PIGA NUP214 TYROBP EFL1 GFI1 TET2 JAK2 KRAS
Protein Mutations 56
C282Y C481S D816V D835Y E255K E255V F317C F317L F317S F317V F31I F359C F359V G250E G71R H369P H63D L248R L248V L265P L858R N291S N682S P13K P140K P1446A P4503A Q12H Q252H R132C R132G R132H R132L R132S R132V R140L R140Q R140W R172G R172K R172M R172S R172W S1612C S9333A T315A T315I T351I T790M V158M V299L V57I V600E V617F V66M Y253H
SNP 17
rs10509681 rs11572080 rs12459419 rs172378 rs2032582 rs230561 rs25531 rs3816527 rs396991 rs429358 rs4880 rs4958351 rs6190 rs628031 rs7412 rs776746 rs904627